Analysts expect over 2018 rising revenue Evotec

Tomorrow the German Evotec will report its past quarter results. Over the current book year the total revenue will be 370,11 million euros (consensus estimates). This is rather significant more than 2017's revenue of 257,63 million euros.

Historical revenues and results Evotec plus estimates 2018

The analysts expect for 2018 a net profit of 50 million euros. Most of the analysts anticipate on a profit per share of 34 cent. The PE-ratio therefore is a significant 66,18.

Analysts don't expect the company to pay a dividend. The average dividend yield of the pharmaceutical companies equals a limited 0,5 percent.

Latest estimates around 20 euros

Berenberg, Deutsche Bank and Oddo Seydler Bank recently provided recommendations for the stock.

Based on the current number of outstanding shares Evotec 's market capitalization is 2,99 billion euros. The Evotec stock was the past 12 months quite volatile. Since last March the stock is even 37 percent higher. This year the stock price moved between 12 and 23 euro. Since 2008 the stock price is almost 2748 percent higher.

At 9.33 the stock trades 0,13 percent lower at 22,5 euros.

Historical stock prices Evotec

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.